Sudden Bullish Activity in Aquinox Pharma (AQXP); Wall Street Surprised with Impinj’s (PI) Results


Aquinox Pharmaceuticals Inc. (Nasdaq:AQXP) stock soared to touch the $13.75 mark in intraday trading Thursday, currently changing hands at $12.48, up $1.86 (or +17.51%) with 2.22M shares traded so far, representing a large increase in activity versus its average volume (3m) of 144,320

There appears to be no confirmed recent news from the clinical-stage pharmaceutical company in the street that may explain the sudden bullish activity in the stock

Aquinox Pharmaceuticals, which engages in discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, has 17.21M Shares Outstanding and AQXP stock 52-range is from $6.01 to $22.38 per share



Shares of Impinj, Inc. (Nasdaq:PI) climbed to reach a new high of $27.92 – since its debut as a public company on July 21 this year – after the company delivered in its quarterly financial results numbers that surpassed Wall Street analysts’ expectations

For the second quarter 2016, Impinj posted revenue of $26.0 million, a 36% increase year over year, and non-GAAP net income of $0.87 million, or $0.06 per diluted share, topping the Capital IQ Consensus Estimate of $0.02 earnings per share on revenues of $25.31 million for the period

PI stock is trading at $27.59, up $4.77 (or +20.90%) and 1.86M of its shares changed hands so far

Impinj, a provider of referral and information network (RAIN) radio frequency identification (RFID) solutions, has 17.60M Shares Outstanding and PI stock range (from its IPO to date) is currently between $16.36 to $27.92 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at